These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8729524)

  • 1. Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women.
    Grey A; Cundy T; Evans M; Reid I
    Clin Endocrinol (Oxf); 1996 Mar; 44(3):293-6. PubMed ID: 8729524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis.
    Grey AB; Cundy TF; Reid IR
    Clin Endocrinol (Oxf); 1994 May; 40(5):671-7. PubMed ID: 8013147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medroxyprogesterone and bone mineral density response to oestrogen.
    Kanis JA
    Clin Endocrinol (Oxf); 1996 Mar; 44(3):297-8. PubMed ID: 8729525
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
    Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy.
    Adachi JD; Sargeant EJ; Sagle MA; Lamont D; Fawcett PD; Bensen WG; McQueen M; Nazir DJ; Goldsmith CH
    Br J Obstet Gynaecol; 1997 Jan; 104(1):64-70. PubMed ID: 8988699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
    Gambacciani M; Ciaponi M; Cappagli B; Genazzani AR
    Am J Obstet Gynecol; 2001 Nov; 185(5):1180-5. PubMed ID: 11717654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
    Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
    BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on bone of oral hormone replacement therapy initiated 2 years after ovariectomy in young adult monkeys.
    Jayo MJ; Register TC; Carlson CS
    Bone; 1998 Oct; 23(4):361-6. PubMed ID: 9763148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women.
    Ongphiphadhanakul B; Chanprasertyothin S; Payatikul P; Tung SS; Piaseu N; Chailurkit L; Chansirikarn S; Puavilai G; Rajatanavin R
    Clin Endocrinol (Oxf); 2000 May; 52(5):581-5. PubMed ID: 10792337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women.
    Orr-Walker BJ; Evans MC; Clearwater JM; Horne A; Grey AB; Reid IR
    Arch Intern Med; 2000 Jul; 160(14):2161-6. PubMed ID: 10904459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
    Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
    Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial.
    Civitelli R; Pilgram TK; Dotson M; Muckerman J; Lewandowski N; Armamento-Villareal R; Yokoyama-Crothers N; Kardaris EE; Hauser J; Cohen S; Hildebolt CF
    Arch Intern Med; 2002 Jun; 162(12):1409-15. PubMed ID: 12076241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial.
    Grey AB; Stapleton JP; Evans MC; Tatnell MA; Reid IR
    Ann Intern Med; 1996 Sep; 125(5):360-8. PubMed ID: 8702086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
    Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
    Osteoporos Int; 2005 Apr; 16(4):372-9. PubMed ID: 15654581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
    Mizunuma H; Shiraki M; Shintani M; Gorai I; Makita K; Itoga S; Mochizuki Y; Mogi H; Iwaoki Y; Kosha S; Yasui T; Ishihara O; Kurabayashi T; Kasuga Y; Hayashi K
    J Bone Miner Metab; 2006; 24(1):11-5. PubMed ID: 16369892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women.
    Davas I; Altintas A; Yoldemir T; Varolan A; Yazgan A; Baksu B
    Fertil Steril; 2003 Sep; 80(3):536-40. PubMed ID: 12969694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.
    Gallagher JC; Kable WT; Goldgar D
    Am J Med; 1991 Feb; 90(2):171-8. PubMed ID: 1847582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
    Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
    N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
    Gallagher JC; Fowler SE; Detter JR; Sherman SS
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
    Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A
    Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.